🇺🇸 FDA
Pipeline program

I-124-CLR1404

DCL-13-002

Phase 2 small_molecule terminated

Quick answer

I-124-CLR1404 for Glioblastoma is a Phase 2 program (small_molecule) at Cellectar Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Cellectar Biosciences
Indication
Glioblastoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials